Novartis, CH0012005267

Novartis stock: UBS keeps CHF 116.00 target for Novartis stock

Published on 10/19/2026 at 15:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis reports third-quarter results on October 27, 2026. Novartis stock costs EUR 134.21 on October 19, 2026, up 0.08 percent versus the Xetra close.

Analyst view and trading date

On October 15, 2026, UBS analyst Matthew Weston set a CHF 116.00 target for Novartis.
Novartis will publish third-quarter results on October 27, 2026.
Novartis stock costs EUR 134.21 at Lang & Schwarz on October 19, 2026 at 3:33 p.m. CEST, 0.08 percent above the Xetra close of October 16, 2026 at EUR 134.10.
Novartis has a market capitalization of CHF 235.30 billion and a P/E ratio of 22.96.

Börsenanzeigetafel mit Candlestick-Charts und Händlern auf einem Schweizer Handelsparkett — Novartis AG CH0012005267 – Börsentafel mit Pharmacharts und Händlern auf belebtem Schweizer Trading-Floor, Illustration mit AI erstellt.

UBS analyst Matthew Weston maintained a Hold rating and set a CHF 116.00 price target for Novartis on October 15, 2026, according to Markets Insider. The target is 6.30 percent below the CHF 123.80 SIX price on October 19, 2026. Novartis stock was trading at EUR 134.21 at Lang & Schwarz on October 19, 2026 at 3:33 p.m. CEST, plus 0.08 percent versus the Xetra close of October 16, 2026 at EUR 134.10.

October 27 results set the date

Novartis will publish its third-quarter results on October 27, 2026, according to the company's investor calendar. The release is the next scheduled reporting event for shareholders. A separate investor call on remibrutinib in multiple sclerosis is scheduled for October 23, 2026, according to Novartis.

Trading range and yearly position

The Lang & Schwarz bid was EUR 134.18 and the ask was EUR 134.24 at 3:33 p.m. CEST on October 19, 2026. The SIX quote was CHF 123.80 at 1:25 p.m. CEST, with a 52-week range of CHF 97.05 to CHF 132.68. That places the home-market price 6.69 percent below the 52-week high and 27.56 percent above the low. The current range puts the stock near its upper yearly boundary, while the euro quote remains the central reference for German investors.

CHF 235.30 billion market value

Novartis had a market capitalization of CHF 235.3 billion, a P/E ratio of 22.96 and a dividend yield of 3.00 percent on October 19, 2026. The second-quarter 2026 results showed revenue of USD 14.95 billion, operating profit of USD 4.75 billion and net income attributable to common shareholders of USD 3.26 billion for the period ended June 30, 2026. Those figures provide a dated operating baseline before the October report.

Comparison with peers

Novartis: plus 0.08 percent, P/E 22.96, market capitalization CHF 235.3 billion

Roche (SIX, CHF): P/E 20.09, market capitalization CHF 256.6 billion

AstraZeneca (LSE, GBp): P/E 24.61, market capitalization GBP 192.7 billion

Price stays near the yearly high

The UBS target remains below the current SIX quotation, while the upcoming October 23 investor call and October 27 results provide the next dated milestones. The euro price was trading at EUR 134.21 at Lang & Schwarz on October 19, 2026 at 3:33 p.m. CEST, plus 0.08 percent versus the Xetra close of October 16, 2026 at EUR 134.10. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.